Reanalyzing a Randomized Controlled Trial of Invasive Aspergillosis Using a Desirability of Outcome Ranking Approach: Voriconazole Versus Amphotericin B Deoxycholate.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 42644615.
- Also identified by DOI 10.1093/cid/ciag457.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Efficacy of antifungal therapy in invasive aspergillosis relies primarily on mortality, overlooking critical measures of treatment response. We used the Mycoses Study Group Education & Research Consortium (MSG) Desirability of Outcome Ranking (DOOR) framework to assess efficacy of antifungal therapies by integrating mortality, treatment failure, and severe adverse events. Voriconazole achieved better overall outcomes than amphotericin B using the DOOR approach.